Compare Fresenius Kabi Onco. with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GSK PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GSK PHARMA FRESENIUS KABI ONCO./
GSK PHARMA
 
P/E (TTM) x 22.1 50.9 43.5% View Chart
P/BV x 3.1 11.5 27.1% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 FRESENIUS KABI ONCO.   GSK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GSK PHARMA
Mar-19
FRESENIUS KABI ONCO./
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1763,595 4.9%   
Low Rs791,253 6.3%   
Sales per share (Unadj.) Rs37.7184.7 20.4%  
Earnings per share (Unadj.) Rs5.126.3 19.4%  
Cash flow per share (Unadj.) Rs6.729.2 23.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5126.3 33.7%  
Shares outstanding (eoy) m158.23169.40 93.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.413.1 25.7%   
Avg P/E ratio x25.092.2 27.1%  
P/CF ratio (eoy) x18.983.1 22.8%  
Price / Book Value ratio x3.019.2 15.6%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m20,135410,626 4.9%   
No. of employees `0001.25.0 23.2%   
Total wages/salary Rs m7035,372 13.1%   
Avg. sales/employee Rs Th5,176.26,306.7 82.1%   
Avg. wages/employee Rs Th610.41,083.1 56.4%   
Avg. net profit/employee Rs Th699.6898.0 77.9%   
INCOME DATA
Net Sales Rs m5,96331,281 19.1%  
Other income Rs m181,023 1.8%   
Total revenues Rs m5,98132,304 18.5%   
Gross profit Rs m1,4306,009 23.8%  
Depreciation Rs m258486 53.1%   
Interest Rs m-266 -433.3%   
Profit before tax Rs m1,2166,540 18.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68287 -23.7%   
Tax Rs m3422,373 14.4%   
Profit after tax Rs m8064,454 18.1%  
Gross profit margin %24.019.2 124.9%  
Effective tax rate %28.136.3 77.5%   
Net profit margin %13.514.2 94.9%  
BALANCE SHEET DATA
Current assets Rs m5,10220,061 25.4%   
Current liabilities Rs m2,38514,543 16.4%   
Net working cap to sales %45.617.6 258.2%  
Current ratio x2.11.4 155.0%  
Inventory Days Days15057 264.3%  
Debtors Days Days11314 805.7%  
Net fixed assets Rs m5,14814,343 35.9%   
Share capital Rs m1581,694 9.3%   
"Free" reserves Rs m6,55619,704 33.3%   
Net worth Rs m6,73221,398 31.5%   
Long term debt Rs m9522 47,610.0%   
Total assets Rs m10,38839,113 26.6%  
Interest coverage x-45.81,091.0 -4.2%   
Debt to equity ratio x0.10 151,337.3%  
Sales to assets ratio x0.60.8 71.8%   
Return on assets %7.511.4 65.8%  
Return on equity %12.020.8 57.5%  
Return on capital %14.631.9 45.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298534 992.1%   
Fx outflow Rs m1,7727,091 25.0%   
Net fx Rs m3,525-6,557 -53.8%   
CASH FLOW
From Operations Rs m1,2743,994 31.9%  
From Investments Rs m-1,204-1,433 84.0%  
From Financial Activity Rs m-196-3,584 5.5%  
Net Cashflow Rs m-126-1,023 12.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 50.7 159.8%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 9.6 23.8 40.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   42,599 102,036 41.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Infosys Dips 4% Post Q4 Results(09:30 am)

Asian share markets are trading on a negative note today following mixed cues from Wall Street.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SANOFI INDIA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS